U.S. Residents Novartis Oncology
4 Rare Diseases Go to Novartis Oncology
     

Atypical Chronic Myeloid Leukemia

Atypical chronic myeloid leukemia (aCML) is a leukemic disorder having both myelodysplastic and myeloproliferative features.1 It differs from classic chronic myeloid leukemia (CML) in 2 important ways: First, whereas the vast majority of cases of CML are associated with the t(9;22)(q43;q11.2) chromosomal translocation (Ph chromosome) and Bcr-Abl fusion gene, aCML is not.2,3 Also, unlike what is seen in the chronic phase of CML, aCML is associated with marked granulocytic and frequently multilineage dysplasia.3

Epidemiology
The incidence of aCML is unknown. The median age at the time of diagnosis has been reported to be between 60 and 80 years;1 however, the disorder can be found in middle-aged patients as well.4


References:
  1. National Cancer Institute. Myelodysplastic/Myeloproliferative Diseases (PDQ®): Treatment. Health Professional Version. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/mds-mpd/healthprofessional/allpages. Accessed April 24, 2006.
  2. Goldman JM, Melo JV. Chronic myeloid leukemia—advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451-1464.
  3. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292-2302.
  4. Hernandez JM, del Canizo MC, Cuneo A, et al. Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. Ann Oncol. 2000;11:441-444.
  Clinical trials

Rare Like Me

Disclaimer: This is an international website dedicated to rare diseases, and intended for healthcare professionals outside the US. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
About Rare Diseases  |  DFSP  |  HES  |  Mast Cell Disease  |  Myelodysplastic / Myeloproliferative Diseases  |  Resources
Contact    |    Sitemap    |    Privacy
Use of this website is subject to our Terms of Use
©2008 Novartis AG